BTC 
ETH 
BNB 
XRP 
SOL 
TRX Moderna stock hits five-year high on vaccine sales beat and raised guidance
Investor's Business Daily reported that Moderna stock surged to a five-year high on Friday after the company posted vaccine sales that beat expectations and raised its full-year guidance. The post also said the cancer vaccine remains the real story for the company.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Moderna stock rose to a five-year high on Friday after its vaccine sales beat expectations.
“Moderna stock surged to a five-year high Friday on the back of its Street-walloping vaccine sales”
Investor's Business Daily -
Moderna raised its guidance for the year.
“its Street-walloping vaccine sales and guidance hike for the year”
Investor's Business Daily -
The post argues Moderna's cancer vaccine is still the real story.
“But The Real Story Is Still Its Cancer Vaccine”
Investor's Business Daily
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-06 18:20 UTC. Labels are computed from the sources, not by the model.